SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Regencell Bioscience Holdings Limited RGC NASDAQ

NASDAQ Capital Marke • Healthcare • Drug Manufacturers - Specialty & Generic • HK • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Regencell Bioscience Holdings Limited (RGC) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $30.11. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: RGC trades at a trailing Price-to-Earnings (P/E) of -3929.2 (S&P 500 average ~25).

Net income is $4M (loss), growing at +21.4%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $544,415 against $5M equity (Debt-to-Equity (D/E) ratio 0.11, conservative). Current ratio is 7.39 (strong liquidity). Debt-to-assets is 9.5%. Total assets: $6M.

Analyst outlook: 0 / 4 analysts rate RGC as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 20/100 (Fail), Income ?/100 (Fail).

RGC SharesGrow Score Overview

67/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 0/100

Valuation — P/E, PEG, Forward PEG

GROWTH 100/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 100/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 46/100

Gross margin is + market cap

FUTURE 20/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — RGC

No analyst coverage available for this stock.

RGC: +0%/yr revenue is, +21.4%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet RGC: Debt-to-Equity (D/E) ratio 0.11 (conservative), Current ratio is 7.39 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

RGC: Gross margin is 0% (+0 pp trend), $15B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.

View details →

Analyst outlook: 0 / 4 analysts rate RGC as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range0.66553-83.6

Volume145.46K

Avg Volume (30D)225.61K

Market Cap$14.89B

Beta (1Y)2.25

Share Statistics

EPS (TTM)-0.01

Shares Outstanding$494.49M

IPO Date2021-07-16

Employees12

CEOYat-Gai Au

Financial Highlights & Ratios

Gross Profit$-392.74K

EBITDA$-3.19M

Net Income$-3.58M

Operating Income$-3.77M

Total Cash$4.9M

Total Debt$544.42K

Net Debt$-1.87M

Total Assets$5.76M

Price / Earnings (P/E)-4181.9

Analyst Forecast

Rating ConsensusHold

Analysts Covering4

Buy 0% Hold 100% Sell 0%

Company Info

CountryHK

ExchangeNASDAQ Capital Marke

CurrencyUSD

ISINKYG7487R1002

Price Chart

RGC

Regencell Bioscience Holdings Limited ↗ · NASDAQ Capital Marke

Healthcare • Drug Manufacturers - Specialty & Generic

0.67 52WK RANGE 83.60

People Also View

Prestige Consumer Healthcare Inc.

Phibro Animal Health Corporation

ANI Pharmaceuticals, Inc.

Collegium Pharmaceutical, Inc.

Procaps Group S.A.

Silver Spike Investment Corp.

RAMM Pharma Corp.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message